Cell Pharm

Cell Pharm GmbH, a subsidiary of STADA Arzneimittel AG, is a German pharmaceutical company specializing in oncology and nephrology. The company is best known for its development and commercialization of biosimilars, most notably Silapo (epoetin kappa), which is used to treat anemia associated with chronic renal failure and chemotherapy. Beyond biosimilars, Cell Pharm provides a range of generic oncology medications and supportive care therapies. It serves as a strategic unit within the STADA Group for high-value specialty pharmaceuticals and complex biologics. The company was a pioneer in the European biosimilar market, being among the first to launch a biosimilar erythropoietin. Its portfolio continues to expand through the integration of STADA's broader specialty and biosimilar pipeline.